ArticlePharmaceutics2022
Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
- From pathogenesis to treatment: the role of autophagic cell death in GONFH and its potential mitigation by naringenin.Theranostics · 2026Article
- Review
- Variations in Plasma Levels of Orally Administered Ivermectin Could Hamper Its Potential Drug Repositioning: Results of a Bioequivalence Study in Mexican Population.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Osteoporosis: Causes, Mechanisms, Treatment and Prevention: Role of Dietary Compounds.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Impact of polyethylene microplastics exposure on kallikrein-3 levels, steroidal-thyroidal hormones, and antioxidant status in murine model: protective potentials of naringin.Scientific reports · 2024Article
- Naringenin modulates the NO‑cGMP‑PKG signaling pathway by binding to AKT to enhance osteogenic differentiation in hPDLSCs.International journal of molecular medicine · 2024Article
- Electrospun sandwich mesh structures loaded with naringenin and vitamin KMaterials today. Bio · 2023Article
- Protective potential of naringenin and its nanoformulations in redox mechanisms of injury and disease.Heliyon · 2023Review
- Nano Drug Delivery Strategies for an Oral Bioenhanced Quercetin Formulation.European journal of drug metabolism and pharmacokinetics · 2023Review
- Herbal Medicine Nanocrystals: A Potential Novel Therapeutic Strategy.Molecules (Basel, Switzerland) · 2023Review
- A Scoping Review of the Skeletal Effects of Naringenin.Nutrients · 2022Article
- Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension.Pharmaceutics · 2022Article
- Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles.Pharmaceutics · 2022Review
- Polymeric Micelles for Breast Cancer Therapy: Recent Updates, Clinical Translation and Regulatory Considerations.Pharmaceutics · 2022Review
- Structural Elucidation of Alkali Degradation Impurities of Favipiravir from the Oral Suspension: UPLC-TQ-ESI-MS/MS and NMR.Molecules (Basel, Switzerland) · 2022Article
- Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects.Pharmaceutics · 2022Review
- The role of circadian rhythm in osteoporosis; a review.Frontiers in cell and developmental biology · 2022Review
- Bioengineering strategies targeting angiogenesis: Innovative solutions for osteonecrosis of the femoral head.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naringenin (NRG) is a flavonoid and has been reported as an anti-osteoporotic agent. However, poor bioavailability may limit the anti-osteoporotic potential of the drug. The purpose of the study was to compare the anti-osteoporotic activity of naringenin nanosuspension (NRG-NS) with the NRG and standard therapeutic drug, raloxifene hydrochloride (RLX). Here, NRG-NS showed anti-osteoporotic activity in MG-63 cells by upregulating the osteocalcin levels. The in vivo anti-osteoporotic activity of NRG-NS was further investigated in an osteoporotic rat model to mimic the post-menopausal condition. The animals were randomized and separated into six groups. The animals were treated with RLX (p.o., 5.4 mg/kg), NRG (p.o., 20 mg/kg), NRG-NS (p.o., 20 mg/kg), and blank-NS for 60 days after completion of a 30-day post-surgery period and compared with control and ovariectomized (OVX) groups. After the treatment, body and uterine weights, biochemical estimation in serum (calcium, phosphorus, acid phosphatase, alkaline phosphatase, osteocalcin), bone parameters (length, diameter, dry weight, density, ash weight, bone mineral content) and bone microarchitecture by histopathology were determined. The results showed the protective effects of NRG-NS on osteoblast-like MG-63 cells. The biochemical estimations confirmed the normalization of parameters viz., alkaline phosphatase, calcium concentrations, and bone density with a decrease in levels of acid phosphatase and inorganic phosphorus with NRG-NS as compared to plain NRG. The results indicated that the oral administration of NRG-NS could be a potential therapeutic formulation for the treatment of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.